FDA Classifies J&J Cerenovus Brain Coil Recall as Class I After Patient Death and Four Injuries

A higher-than-expected failure-to-detach rate in CEREPAK embolic coils has been linked to hemorrhagic and ischemic stroke, prompting the FDA's most serious recall tier.

The U.S. Food and Drug Administration has classified the recall of Johnson & Johnson MedTech’s CEREPAK Detachable Coil System as Class I — the agency’s most serious recall tier, reserved for products reasonably likely to cause serious adverse health consequences or death — following reports of four serious injuries and one patient death linked to a higher-than-expected failure-to-detach rate.

CEREPAK coils are used in endovascular embolization of intracranial aneurysms: a neurosurgeon or interventional radiologist threads a microcatheter through a blood vessel to the site of the aneurysm and deploys the coil, which fills the sac and promotes clotting to prevent rupture. When a coil fails to detach from its delivery wire as intended, it cannot be positioned correctly — creating risks of hemorrhagic stroke (from aneurysm rupture or vessel injury) or ischemic stroke (from thrombus formation), and potentially necessitating open surgical intervention.

J&J MedTech and its subsidiary Cerenovus initiated a voluntary recall on October 2, 2025, after an internal evaluation identified that the detachment failure rate may be higher than anticipated. As of October 14, 2025 — the data cut-off date cited in FDA records — the company had received reports of four serious injuries and one death associated with the defect. The FDA formally announced the Class I classification on February 5, 2026.

Affected Devices

The recall covers approximately 12,000 units across eleven product lines in the Uniform, Heliform, and Freeform families, including the CEREPAK Uniform, Uniform XL, Uniform 3D, Heliform Soft, Heliform XtraSoft, Heliform XL, Heliform XtraSoft XL, Freeform, Freeform Mini, Freeform XtraSoft, and the CEREPAK Detacher Handle.

A note on classification terminology: The CEREPAK is a Class III medical device under FDA’s regulatory framework — the highest-risk device class, requiring premarket approval (PMA). This is distinct from the recall’s Class I designation, which describes the severity of the health risk posed by the defective units, not the regulatory authorization pathway.

What Clinicians Should Do Now

Facilities holding affected inventory should immediately stop using all affected units; identify and physically segregate affected stock; notify all relevant clinical staff and any external facilities that received affected products; and contact J&J MedTech sales representatives for help identifying suitable alternatives. No date for return to market has been announced. Clinicians with concerns about patients who received procedures with affected coils should follow institutional adverse event protocols and may report to the FDA’s MedWatch program.

Trials Today

Phase 3 ZENITH / zilebesiran (siRNA antihypertensive) — 11,000-patient CV outcomes trial; composite endpoint of CV death, MI, stroke, HF hospitalization over ~5 years; twice-yearly dosing investigational.

Phase 3 COMBINE 2 / IcoSema (insulin icodec + semaglutide) — 683-patient trial in T2DM inadequately controlled on GLP-1 RA; 52-week results posted with HbA1c change as primary endpoint.

Phase 3 CONVOKE / CT-155 digital therapeutic for schizophrenia — 464-patient trial for negative symptoms of schizophrenia (Click Therapeutics/Boehringer Ingelheim); primary endpoint completed June 2025, results pending.

Phase 3 PRIOH-1 / pritelivir for acyclovir-resistant HSV — 158-patient trial in immunocompromised patients; novel helicase-primase inhibitor; completed November 2025, results imminent.

Phase 3 PREGnant / elagolix pre-IVF in endometriosis — NIH/NICHD-funded, 103-patient trial at Yale; live birth rate primary endpoint; completed May 2025, results posted.

At the Agencies

BD ChloraPrep / FREPP — Nationwide Voluntary Recall — Aspergillus penicillioides contamination in specific lots of ChloraPrep 1 mL and FREPP 1.5 mL chlorhexidine skin-prep applicators; risk of sepsis and death in surgical patients; distributed to hospitals March-June 2024.

J&J Cerenovus CEREPAK — Class I Recall — Higher-than-expected failure-to-detach rate linked to four serious injuries and one death; risks include hemorrhagic/ischemic stroke; ~12,000 units across 11 product lines.

GE HealthCare MIM Contour ProtegéAI+ 2.0 — FDA 510(k) Clearance — First radiation oncology AI software cleared with a Predetermined Change Control Plan (PCCP), allowing model updates without new 510(k) submissions; cleared June 4, 2026.